Interview with Alex Mayweg, partner at Versant Ventures and president of Ridgeline, a Versant Ventures Discovery Engine – Located in the Technologiepark Basel
“We make no compromises in creating the highest potential Company”
Versant Ventures has a strong history in building successful companies such as Therachon, Black Diamond or CRISPR Therapeutics. We talked to Alex Mayweg, partner at Versant Ventures in Basel, about the beauty of Versant Ventures discovery engine Ridgeline Therapeutics, translating science into successful drug development programs and the future of drug discovery.
Technologiepark Basel in 2020
TargImmune successfully closed its 2021 financing round and ...
Monte Rosa Therapeutics raises USD222 million in successful ...
Alentis Therapeutics Raises USD 67 Million in Series B Fina...
Virtual Auditorium Talk: ‘How to attract and retain best t...